HomeAI · summaries
Storia in 4 fonti
Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines
Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Silence Therapeutics aims at Takeda with new data in rare blood cancer
A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.
- ·
endpoints.news
Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer
Silence Therapeutics' divesiran hits its Phase 2 target in polycythemia vera, setting up a Phase 3 trial
